LLY · News · 20261106N

Foghorn Collaboration Termination

ELI LILLY & Co · 2026-11-06 · Importance 31 · Surprise 42

Foghorn Therapeutics announced it would not advance the FHD-909 and Selective SMARCA2 degrader programs developed in collaboration with Lilly. The report gives no financial terms or timing for the decision. It also reports that Foghorn reduced its workforce by 40%, but does not attribute that reduction specifically to Lilly.

Key facts